



Bradley T. Wyman

PhD

PROFESSIONAL SUMMARY

A recognized expert with more than twenty years of experience with clinical imaging studies. Experience includes 10 years at Pfizer developing and implementing imaging biomarkers in clinical studies across therapeutic areas. Formerly Vice President of Imaging and Clinical Development at ImaginAb, where responsible for the development and clinical testing of novel PET tracers. Working with multiple medical device startups, responsibilities included software and hardware development, Quality Systems Regulations (QSR), 510k submissions, and clinical testing.

CONTACT

+1 - 215-648-1208 Ext. 705

BWyman@thebrackengroup.com

[LinkedIn Profile](#)

www.thebrackengroup.com

EDUCATION

Bachelor of Science 1988

Brigham Young University,
Electrical Engineering

Master of Science 1991

Northwestern University,
Electrical Engineering

Doctor of Philosophy 1999

Johns Hopkins University,
Biomedical Engineering

PUBLICATIONS

For a complete list of approximately 120 publications click here:

<https://scholar.google.com/citations?user=K9A5RqQAAAAJ&hl=en>

PROFESSIONAL EXPERIENCE

Aug 2018 – Present **The Bracken Group**

Partner

- Advise pharma, biotech, medical device, investment, and service companies on strategy, clinical study design, process management, governance, and business development and help to identify growth and strategic opportunities.
- Designed and implemented clinical components for a phase 1 study of a novel imaging agent. Included development and writing of the protocol, investigator's brochure, pharmacy manual, informed consent forms, and other documents as required for Investigational Review Board (IRB) approval.
- Conducted due diligence on behalf of investors to evaluate novel technologies for product development. Created comprehensive business plans including proposed paths for: technology development, validation, regulatory approval, technical and business de-risking, company structure, and financing. Recommendations were used to make final investment decisions.

May 2020 – Present **NanoClinical, LTD**

Founder, V.P. Quality and Operations

- Codeveloped with the leadership team business, marketing, funding, and scientific strategies. Led the grant submission effort to obtain non-dilutive funding.
- Operationalizing a novel high-throughput microscopy technology to help design and develop better cancer treatments for patients. (www.nanoclinical.com)

Aug 2015 – 2018 **Othree Consulting, LLC**

CEO

- Helping biotechnology and pharmaceutical companies advance their ideas into life-impacting solutions for patients. Clients range from small startup companies to major pharmaceutical companies.
- Conducted literature searches to answer specific research questions and evaluate emerging technologies for fitness for use. Delivered to clients as short research reports with recommendations as supported by existing published literature.
- Conducted business development to win new opportunities for clients by leveraging personal network and facilitating introductions. Coauthored work proposals to help clients win new business.
- Helped a client build business by developing and implementing an electronic media strategy to promote the client's internet presence. Made recommendations for developing their website and their presence on LinkedIn, Facebook, Twitter, Google+ and YouTube. Also, developed a strategy for blogging and publications.
- Generated critical study documentation including protocols, FDA annual reports, clinical study reports (CSR) and preclinical technical reports

PATENTS

- System and Method for Mining Quantitative Information from Medical Images
V. Chalana, S. Fogarasi, L. Ng, J. Oelund, S. Pathak, S. Racki, B. Sparks, B. Wyman
U.S. Patent No. 7,158,692, Jan 2, 2007
- A System and Method for Determining Convergence of Image Set Registration
B.T. Wyman, L. Ng, U.S. Patent 7,106,891, Sept. 12, 2006.
- Convolution Filtering of Similarity Data for Visual Display of Enhanced Image
C.L. Stork, B.T. Wyman, U.S. Patent No. 6,674,880, Jan. 6, 2004
- Voice Messaging System with Voice Activated Prompt Interrupt
M.A. Johnson, S.A. O'Brien, B.T. Wyman,
U.S. Patent No. 5,155,760, Oct. 13, 1992

May 2014 –
Jul 2017

ImaginAb, Inglewood, CA

VP Imaging and Clinical Development

- As an Executive Team member, maximized shareholder return by delivering the corporate objectives to advance a portfolio of PET radiolabeled molecular antibody fragments for the detection of cancer and immuno-oncology targets.
- Successfully transitioned the company from a startup-stage to a stable growth-stage company by implementing Target Asset Profile and Project Management systems.
- Accelerated the value of the company's portfolio by developing and executing the phase 2 clinical program for 89Zr-Df-IAB2M, a minibody directed against the prostate specific membrane antigen (PSMA). Responsible for study design, protocol development, vendor and site selection and management, study delivery, oversight of analysis and development of the clinical study reports (CSR). Designed the phase 2 program to balance regulatory, scientific, and corporate objectives.
- Led the team responsible for the successful writing and subsequent award of a \$3M non-dilutive Small Business Initiative Research (SBIR) grant.

Jan 2004 –
May 2014

Pfizer, Groton, CT

Head Functional and Structure Neuroimaging; Director, Imaging, Molecular Medicine

- Led the team responsible for designing and implementing biomarkers for the development of drugs in the neurodegenerative, psychiatric, and pain therapeutic areas including Alzheimer's disease, Parkinson's disease, cerebral amyloid angiopathy, post-traumatic stress disorder (PTSD), Huntington's disease, depression, schizophrenia, fibromyalgia, and pain.
- Managed the technological development from concept through deployment of imaging biomarkers for enhancing clinical decision-making during Phase I through Phase 4 drug testing. Actively managed programs in the Cardiovascular, Metabolic Disease, Inflammation, CNS, Pain, and Ophthalmology therapeutic areas.
- Responsible for developing and guiding direct reports, academic groups, contract research organizations (CROs) and external alliances to ensure the successful deployment of imaging in clinical studies for decision making. Creatively applied technical and managerial skills to implement strategies, resolve problems and ensure that the imaging endpoints successfully achieved the designed goals.
- Ensured the successful execution of the imaging for multiple early and late phase Alzheimer's disease studies, including the phase 3 bapineuzumab program. Worked with key opinion leaders and CROs to ensure proper implementation of safety and efficacy biomarkers including CSF biomarkers, volumetric MRI, florbetapir (AV-45), and 11C-PIB PET.
- Designed, developed, and implemented imaging biomarker programs (X-ray and MRI) to support the new drug application (NDA) for tofacitinib (Xeljanz). Studies were conducted in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
- Responsible for the technical execution of multi-year methods study for evaluating existing and exploratory biomarkers for osteoarthritis (approximately \$12M investment). Results from this study were applied to optimize the trial design of a disease modifying osteoarthritis drug.
- Led the team responsible for the design and implementation of the repository for storage of large datasets such as images, ECG, EEG, etc. Worked to build consensus across the organization to expand the utility of the system for multiple customers.

2003 –
2004

Computerized Medical Systems

Director of Development

- Responsible for implementing Quality System Regulation (QSR), achieving ISO 9001 certification, and obtaining 510(k) clearance for image guided brachytherapy.

2003 –
2004

Insightful Corp. Seattle, WA
Senior Research Scientist

1998 –
2000

Confirma Inc. Kirkland, WA
Senior Research Scientist